A Phase 2 interventional study of PF-03084014 and PF-03084014 in Triple Negative Breast Neoplasms, sponsored by Pfizer. Terminated at 37 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Triple Negative Breast Neoplasms by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Triple Negative Breast Neoplasms · Pfizer.
Among the 18 studies in Triple Negative Breast Neoplasms by Pfizer, this one is the 18th largest by enrollment, is one of 2 that started in 2015, is one of 2 in phase 2, and was the 8th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →2 of the 18 studies in Triple Negative Breast Neoplasms by Pfizer are open now, in 11 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Spain
Ages 18+
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, Belgium, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5
First in 2011; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 122 across the 18 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Triple Negative Breast Neoplasms by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
Drug: PF-03084014
Tablet, 10 mg, twice a day.
Tablet, 50 mg, twice a day
Tablet, 100 mg, twice a day
Objective Response (OR) Rate in Participants With Advanced Triple Receptor-Negative Breast Cancer (mTNBC) Harboring Activating Genomic Alterations in Notch Receptors (NA+)
OR status based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis less than \[\<\]10 millimeter \[mm\]). PR: Greater than or equal to (\>=)30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.
Time frame: Cycle 3 Day 1, Cycle 5 Day 1, and every 6 weeks for subsequent cycles ntil disease progression, patient refusal for further follow up, or start of another anti-cancer treatment, whichever occurred first.
OR Rate in Participants With mTNBC Whose Tumors Tested Negative for Eenomic Alterations in Notch Receptor (NA-)
OR status based on assessment of confirmed CR or confirmed PR according to RECIST 1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis \<10 mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.
Time frame: Cycle 3 Day 1, Cycle 5 Day 1, and every 6 weeks for subsequent cycles ntil disease progression, patient refusal for further follow up, or start of another anti-cancer treatment, whichever occurred first.
Progression-Free Survival (PFS) in Participants With NA+ or NA mTNBC
The period from study entry until disease progression, death, whichever occurred first as per RECIST version 1.1.
Time frame: 2 years
Duration of Response (DR) in Participants With NA+ or NA mTNBC
Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause. DR was calculated for the subgroup of patients with a confirmed objective tumor response. Objective Progression (PD): 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: 2 years
One-Year Survival Probability in Participants With NA+ or NA mTNBC
Overall survival (OS) status (alive or not) at 1 year after study entry. The the survival probability at 1 year was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.
Time frame: 1 year
Overall Survival (OS) in Participants With NA+ or NA mTNBC
OS was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.
Time frame: 2 years
Type of Notch Genomic Alterations in Participants With NA+ mTNBC
Type of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC
Time frame: 2 years
Pre-dose Serum Concentration (Ctrough) for PF-03084014
Time frame: Day 1 of Cycle 1, 2, 3, and 5
Pharmacodynamic (PD) Effects of PF-03084014 in Tumor Specimens and Peripheral Blood
Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.
Time frame: Day 1 of Cycle 1, 2, 3, and 5
Alterations in Genes, Proteins, and RNAs Relevant to the Notch Signaling Pathway, to TNBC Biology, and to Sensitivity/Resistance to PF-03084014 in Tumor Specimens and Peripheral Blood.
Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.
Time frame: Day 1 of Cycle 1, 2, 3, and 5
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as all deaths, regardless of cause, from treatment start until 28 days after the last dose and non-fatal events occurring after treatment start regardless of cause, up until 28 days after the last dose or until start of new anti-cancer treatment, whichever was first.
Time frame: 2 years
Number of Participants With Treatment-Emergent AEs by CTCAE Grade
An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. AEs were defined according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time frame: 2 years
Number of Participants With Laboratory Test (Hematology) Abnormalities
Number of participants with CTCAE version 4.03 grade 1 to 4 hematological test abnormalities.
Time frame: Day 1 of Cycles 1, 2, 3, 4, 5, and subsequent cycles.
Number of Participants With Laboratory Test (Chemistry) Abnormalities
Number of participants with CTCAE version 4.03 grade 1 to 4 chemistry test abnormalities
Time frame: Day 1 and Day 15 of Cycles 1, 2, 3, 4, 5, and subsequent cycles up to Cycle 8 and Day 8 of Cycle 1
Number of Participants With Laboratory Test (Urinalysis) Abnormalities
Number of participants with CTCAE version 4.03 grade 1 to 4 urinalysis test abnormalities for urine protein.
Time frame: Day 1 of Cycle 1
Number of Notch Genomic Alterations in Participants With NA+ mTNBC
Number of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC
Time frame: 2 years
| Milestone | PF-03084014 |
|---|---|
| Started | 19 |
| Completed | 0 |
| Not completed | 19 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 1 |
| Withdrew: Global deterioration of health status | 1 |
| Withdrew: Objective progression or relapse | 10 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Other | 3 |
OR status based on assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis less than \[\<\]10 millimeter \[mm\]). PR: Greater than or equal to (\>=)30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.
No measurements were reported for this outcome.
OR status based on assessment of confirmed CR or confirmed PR according to RECIST 1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease and all target nodes decreased to normal size (short axis \<10 mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. OR=CR+PR.
No measurements were reported for this outcome.
The period from study entry until disease progression, death, whichever occurred first as per RECIST version 1.1.
No measurements were reported for this outcome.
Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause. DR was calculated for the subgroup of patients with a confirmed objective tumor response. Objective Progression (PD): 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm.
No measurements were reported for this outcome.
Overall survival (OS) status (alive or not) at 1 year after study entry. The the survival probability at 1 year was summarized as a product limit estimator based on the Kaplan-Meier method to account for censored events.
No measurements were reported for this outcome.
OS was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.
No measurements were reported for this outcome.
Type of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.
No measurements were reported for this outcome.
Original diagnostic tumor tissue or the most recent metastatic tumor (archival or de novo biopsy), plasma, and peripheral blood samples were collected for biomarker assessments of circulating analytes, immunohistochemistry for notch receptors expression, expression of notch pathway components and modulators, mutational analysis of pathway and disease associated genes.
No measurements were reported for this outcome.
An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as all deaths, regardless of cause, from treatment start until 28 days after the last dose and non-fatal events occurring after treatment start regardless of cause, up until 28 days after the last dose or until start of new anti-cancer treatment, whichever was first.
| participants | PF-03084014 |
|---|---|
| Number of Participants with AEs | 18 |
| Number of Participants with SAEs | 6 |
An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. AEs were defined according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
| participants | PF-03084014 |
|---|---|
| Any AEs, Grade 1 | 1 |
| Any AEs, Grade 2 | 5 |
| Any AEs, Grade 3 | 9 |
| Any AEs, Grade 4 | 1 |
| Any AEs, Grade 5 | 2 |
Number of participants with CTCAE version 4.03 grade 1 to 4 hematological test abnormalities.
| participants | PF-03084014 |
|---|---|
| Anemia | 12 |
| Lymphocyte count increased | 0 |
| Lymphopenia | 11 |
| Neutrophils (absolute) | 0 |
| Platelets | 3 |
| White blood cells | 4 |
Number of participants with CTCAE version 4.03 grade 1 to 4 chemistry test abnormalities
| participants | PF-03084014 |
|---|---|
| Alanine aminotransferase | 5 |
| Alkaline phosphatase | 6 |
| Aspartate aminotransferase | 9 |
| Bilirubin (total) | 1 |
| Creatine kinase | 1 |
| Creatinine | 13 |
| Gamma glutamyl transferase | 1 |
| Hypercalcemia | 3 |
| Hyperglycemia | 13 |
| Hyperkalemia | 3 |
| Hypermagnesemia | 1 |
| Hypernatremia | 0 |
| Hypoalbuminemia | 8 |
| Hypocalcemia | 4 |
| Hypoglycemia | 1 |
| Hypokalemia | 5 |
| Hypomagnesemia | 3 |
| Hyponatremia | 6 |
| Hypophosphatemia | 14 |
Number of participants with CTCAE version 4.03 grade 1 to 4 urinalysis test abnormalities for urine protein.
| participants | PF-03084014 |
|---|---|
| Number of Participants With Laboratory Test (Urinalysis) Abnormalities | 2 |
Number of notch genomic alterations identified by NGS assay in patients with NA+ mTNBC
No measurements were reported for this outcome.
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-03084014 | — | 6/19 (31.6%) | 18/19 (94.7%) |
| Event | PF-03084014 |
|---|---|
| Confusional statePsychiatric disorders | 2/19 |
| Disease progressionGeneral disorders | 1/19 |
| PyrexiaGeneral disorders | 1/19 |
| Lung infectionInfections and infestations | 1/19 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/19 |
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/19 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/19 |
| Event | PF-03084014 |
|---|---|
| DiarrhoeaGastrointestinal disorders | 11/19 |
| NauseaGastrointestinal disorders | 8/19 |
| FatigueGeneral disorders | 8/19 |
| VomitingGastrointestinal disorders | 7/19 |
| HypophosphataemiaMetabolism and nutrition disorders | 7/19 |
| PyrexiaGeneral disorders | 5/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/19 |
| DyspepsiaGastrointestinal disorders | 3/19 |
| Mucosal inflammationGeneral disorders | 3/19 |
| ConjunctivitisInfections and infestations | 3/19 |
| Age, Continuous(years) | PF-03084014 |
|---|---|
| Mean | 57.4 ± 12.1 |
| Sex: Female, Male(Participants) | PF-03084014 |
|---|---|
| Female | 19 |
| Male | 0 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2015 to primary completion in Jan 2016, 11 months.
Results were first posted in Jan 2017, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirogacestat
Triple Negative Breast Neoplasms →